

Parenteral Drug Delivery Systems

Introduction



Small molecules with poor or variable oral bioavailability or biologics are delivered via parenteral routes. To avoid frequent injections due to short half-life, compliance issue or a narrow therapeutic window, controlled release parenteral systems play an important role. To deliver the drug in a predictable manner at a controlled rate, different approaches are being used at Pensatech Pharma.

Our approach:

Every product with its characteristics and desired performance profile requires the development of a specific formulation and process. Defining a target product profile, appropriate scientific approaches are evaluated from different technologies:

- ✓ Depot formulations (aqueous and oily solutions and micro- and nano-suspensions)
- ✓ Biodegradable nano-/ microparticles (various encapsulation methods and carriers)
- ✓ Implants (HME, in situ forming implants)
- ✓ Multivesicular and conventional liposomes

The selection for the lead formulation technology is based on our prior experience, a mechanistic model and data generated. The formulation and processing is developed on a series of performance testing including suitable in-vitro dissolution testing.



Application examples of PLGA DDS with long and flexible delivery periods




Fig. 1 In vitro drug release from different PLGA DDS

- ✓ Broad experience with various APIs (small molecules, peptides, proteins) and PLGA grades including a mechanistic understanding of the drug release characteristics (→ Hydrolysis → Erosion → Drug release)




Fig. 2 Example of an actual and modelled release profile from PLGA DDS

Case reports of successful partnerships:

- ✓ Prototype development for toxicology studies (hormone biodegradable implants and microparticles, lipid microparticles for veterinary use)
- ✓ Formulation, process and analytical development of a freeze-dried powder of cytotoxic drug
- ✓ Formulation development/ feasibility studies for liposome formulations and depot aqueous suspension.
- ✓ Process understanding and scale-up of biodegradable implants

Summary

- ✓ Development of a long-acting parenteral formulation requires an in-depth analysis of the API and a tailored formulation technology.
- ✓ The technology selected is based on a mechanistic model of the drug release.
- ✓ Understanding the critical material attributes and critical process parameter is key during the development of a commercial product.